HIV antiretroviral prophylaxis for injecting drug users [4]

The Lancet

Volumn 382, Issue 9895, 2013, Pages 854-855

  Craig, Andrew P ^a   Gray, Richard ^a   Jansson, James ^a   Wilson, David P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR;

COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INTRAVENOUS DRUG ABUSE; LETTER; PRIORITY JOURNAL; SCALE UP; UNITED STATES;

EID: 84883525191     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61856-5     Document Type: Letter

References (5)

1. Choopanya K, Martin M, Suntharasamai P., et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381: 2083-90.
2. Paltiel AD, Freedberg KA, Scott C.A., et al. HIV pre-exposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48: 806-15.
3. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions. http://www.msfaccess.org/sites/default/files/ MSF-assets/HIV-AIDS/Docs/AIDS-report-UTW15-ENG-2012.pdf (accessed June 28, 2013).
4. Kwon JA, Anderson J, Kerr C.C., et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS 2012, 26: 2201-10.
5. Zhang L, Yap L, Xun Z., Wu Z, Wilson D. Needle and syringe programs in Yunnan, China yield health and financial return. BMC Public Health 2011, 11: 250.